2022 LCRF and EGFR Resisters Research Grant on EGFR-Driven Lung Cancer
Luke Hoeppner, PhD
University of Minnesota, Twin Cities
Predictive biomarkers and new therapeutic strategies to prevent EGFR TKI-refractory lung cancer progression
Lung cancer remains the leading cancer related cause of death due to the large number of patients diagnosed with advanced stage disease and the development of resistance to current therapies. The proposed research seeks to understand how lung tumor cells evade therapy-induced cytotoxicity and aims to develop new innovative strategies and therapies to predict and prevent the emergence of treatment refractory cancer progression. The collective impact of this research is providing fundamental knowledge that will improve the quality of life and clinical outcome for individuals afflicted with cancer.